摘要
目的系统评价血管生成素-2(Ang-2)的表达情况与骨肉瘤的关系,以期为骨肉瘤的预后评价提供循证学依据。方法在PubMed、Web of Science、Embase、Cochrane图书馆、中国生物医学文献数据库、中国知网、维普全文数据库、万方知识服务平台等数据库检索相关文献,根据纳入和排除标准筛选关于Ang-2的表达情况与骨肉瘤关系的队列研究并进行资料提取、质量评价及Meta分析;通过亚组分析观察不同临床分期对研究结果的影响。结果本研究最终纳入5篇相关文献,共386例患者。Meta分析结果显示,试验组患者Ang-2的表达水平明显高于对照组(P﹤0.01)。Ⅱb期骨肉瘤中Ang-2的表达水平明显高于Ⅱa期,Ⅲ期骨肉瘤中Ang-2的表达水平明显高于Ⅱb期(P﹤0.01)。两组不同性别骨肉瘤患者Ang-2的表达水平比较,差异无统计学意义(P﹥0.05)。结论根据现有文献表明,Ang-2在骨肉瘤中呈高表达,且与患者的分期、肿瘤直径及肺转移情况密切相关,可以作为骨肉瘤预后的重要标志物。
Objective To systematically evaluate the relationship between the expression of angiopoietin-2(Ang-2)and osteosarcoma,so as to provide evidence-based evidence for prognosis evaluation of osteosarcoma.Method The relevant literatures were retrieved from PubMed,Web of Science,Embase,Cochrane Library,China Biology Medicine,China National Knowledge Infrastructure,VIP and Wanfang knowledge service platform.According to the inclusion and exclusion criteria,cohort studies on the relationship between the expression of Ang-2 and osteosarcoma were screened,and the data extraction,quality evaluation and Meta-analysis were conducted,the influence of different clinical stages on the research results was observed by subgroup analysis.Result 386 patients were included in 5 related literatures.The results of Meta-analysis showed that the expression level of Ang-2 in experimental group was significantly higher than that in control group(P<0.01).The expression level of Ang-2 in stage Ⅱb osteosarcoma was significantly higher than that in stage Ⅱa,and the expression level of Ang-2 in stage Ⅲ osteosarcoma was significantly higher than that in stage Ⅱb(P<0.01).Comparison of Ang-2 expression levels between the two groups of osteosarcoma patients of different genders showed no statistically significant difference(P>0.05).Conclusion According to the existing literature,Ang-2 is highly expressed in patients with osteosarcoma,and it is closely related to different stages,different diameters and lung metastasis.Ang-2 can be used as an important prognostic marker of osteosarcoma.
作者
徐文飞
梅其杰
郭锦荣
卢智贤
叶永生
邹旨龙
段戡
XU Wenfei;MEI Qijie;GUO Jinrong;LU Zhixian;YE Yongsheng;ZOU Zhilong;DUAN Kan(Graduate College Guangxi University of Chinese Medicine,Nanning 530000,Guangxi Zhuang Autonomous Region,China;Department of Orthopaedics of Joint Trauma,the First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530023,Guangxi Zhuang Autonomous Region,China)
出处
《癌症进展》
2020年第18期1853-1857,1931,共6页
Oncology Progress
基金
校级一般硕士研究生科研创新项目(YJSP201728)
广西中医药民族医药自筹经费科研课题(GZZC15-12)
2015年广西中医药大学校级科研项目(2015MS007)。
